Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab
DOI:
https://doi.org/10.2340/actadv.v104.40801Keywords:
drug induced lupus erythematosus, immune checkpoint inhibitor, PD-L1 inhibitor, pembrolizumab, subacute cutaneous lupus erythematosusAbstract
Abstract is missing (Short Communication)
Downloads
References
Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167: 296-305.
https://doi.org/10.1111/j.1365-2133.2012.10969.x DOI: https://doi.org/10.1111/j.1365-2133.2012.10969.x
Raschi E, Antonazzo IC, Poluzzi E, De Ponti F. Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Ann Rheum Dis 2021; 80: e120.
https://doi.org/10.1136/annrheumdis-2019-215819 DOI: https://doi.org/10.1136/annrheumdis-2019-215819
Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020; 31: 724-744.
https://doi.org/10.1016/j.annonc.2020.03.285 DOI: https://doi.org/10.1016/j.annonc.2020.03.285
Rong Y, Bentley JP, Bhattacharya K, Yang Y, Chang Y, Earl S, et al. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer. Cancer Med 2024; 13: e6879.
https://doi.org/10.1002/cam4.6879 DOI: https://doi.org/10.1002/cam4.6879
Bhardwaj M, Chiu MN, Sah SP. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol 2022; 41: 73-90.
https://doi.org/10.1080/15569527.2022.2034842 DOI: https://doi.org/10.1080/15569527.2022.2034842
Bolton C, Chen Y, Hawthorne R, Schepel IRM, Harriss E, Hofmann SC, et al. Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus. Drugs R D 2020; 20: 319-330.
https://doi.org/10.1007/s40268-020-00320-5 DOI: https://doi.org/10.1007/s40268-020-00320-5
Kosche C, Owen JL, Choi JN. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Dermatol Online J 2019; 25: 13030/qt4md713j8.
https://doi.org/10.5070/D32510045821 DOI: https://doi.org/10.5070/D32510045821
Shao K, McGettigan S, Elenitsas R, Chu EY. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol 2018; 45: 74-77.
https://doi.org/10.1111/cup.13059 DOI: https://doi.org/10.1111/cup.13059
Zitouni NB, Arnault JP, Dadban A, Attencourt C, Lok CC, Chaby G. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res 2019; 29: 212-215.
https://doi.org/10.1097/CMR.0000000000000536 DOI: https://doi.org/10.1097/CMR.0000000000000536
Liu RC, Sebaratnam DF, Jackett L, Kao S, Lowe PM. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol 2018; 59: e152-154.
https://doi.org/10.1111/ajd.12681 DOI: https://doi.org/10.1111/ajd.12681
Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lianet CG, et al. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol 2021; 46: 328-337.
https://doi.org/10.1111/ced.14449 DOI: https://doi.org/10.1111/ced.14449
Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 2019; 181: 580-583.
https://doi.org/10.1111/bjd.17245 DOI: https://doi.org/10.1111/bjd.17245
Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Bipin Mathew B, Mitra A. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res 2019; 29: 338-341.
https://doi.org/10.1097/CMR.0000000000000587 DOI: https://doi.org/10.1097/CMR.0000000000000587
Andersson NW, Zachariae C, Simonsen AB. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy. Eur J Cancer 2021; 145: 168-170.
https://doi.org/10.1016/j.ejca.2020.12.017 DOI: https://doi.org/10.1016/j.ejca.2020.12.017
Gambichler T, Doerler M, Scheel CH. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer. Lupus 2021; 30: 531-533.
https://doi.org/10.1177/0961203320983448 DOI: https://doi.org/10.1177/0961203320983448
Ogawa-Momohara M, Muro Y, Goto K, Obuse C, Satoh M, Kono M, et al. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. J Dermatol 2020;47: e217-e219.
https://doi.org/10.1111/1346-8138.15316 DOI: https://doi.org/10.1111/1346-8138.15316
Fietz S, Fröhlich A, Mauch C, de Vos-Hillebrand L, Fetter T, Landsberg J, et al. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab: a case report. Front Immunol 2023; 14: 1324231.
https://doi.org/10.3389/fimmu.2023.1324231 DOI: https://doi.org/10.3389/fimmu.2023.1324231
Diago A, Hueso L, Ara-Martín M, Abadías-Granado I. Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review. Australas J Dermatol 2021; 62: e347-349.
https://doi.org/10.1111/ajd.13538 DOI: https://doi.org/10.1111/ajd.13538
Manjunath J, Mochel M, Nutan F. Nivolumab-induced de novo discoid lupus erythematosus. Case Rep Dermatol 2022; 14: 88-92.
https://doi.org/10.1159/000523800 DOI: https://doi.org/10.1159/000523800
Khorasanchi A, Korman AM, Manne A, Meara A. Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Front Med (Lausanne) 2024; 11: 1334718.
https://doi.org/10.3389/fmed.2024.1334718 DOI: https://doi.org/10.3389/fmed.2024.1334718
Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002; 46: 600-603.
https://doi.org/10.1067/mjd.2002.114608 DOI: https://doi.org/10.1067/mjd.2002.114608
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Dimitrii Pogorelov, Heribert Strotkötter, Vesna Bjelic-Radisic, Ulrich Wesselmann, Jonas Hübinger, Simona Sabulyte, Silke C. Hofmann, Galina Balakirski
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
